November 16, 2016
Wellesley, Mass., Nov 16, 2016 – Bioprinting is rapidly emerging as a tool for producing 3-D cell cultures and tissues. BCC Research reveals in its new report that the global market for bioprinting is forecast to achieve an annual growth rate exceeding 43% through 2021.
Bioprinting has origins in several technologies, including 3-D printing, additive manufacturing, tissue engineering, and synthetic biology. The main elements of bioprinting encompass computer-aided design for patterning and assembly of living and non-living materials with 2-D or 3-D structure. The bioprinted structures are used in various applications like in vitro assays for regenerative medicine and in drug development and testing. The main market applications are in research and applied (collectively, non-clinical) and clinical.
The global market for bioprinting should reach $295 million and $1.8 billion million in 2016 and 2021, respectively, demonstrating a five-year compound annual growth rate (CAGR) of 43.9%. The nonclinical bioprinting applications (mostly applied research) is expected grow from $295 million in 2016 to $635.2 million by 2021, reflecting a five-year CAGR of 16.6%. The global clinical application segment should reach almost $1.2 billion by 2021.
Key industries such as the drug and cosmetics industries are pursuing bioprinting as a technology to manufacture realistic in vitro models for toxicity and disease modeling. Bioprinted 3-D constructs have demonstrated remarkable potential for in vitro models by mimicking in vivo states. Beyond in vitro models, 3-D printing has enormous potential in regenerative medicine applications for tissue grafting and organ replacement, as well.
Advances in bioprint capabilities such as enhanced preservation of living cells during printing processes, the capability to simultaneously print multiple bioink types, innovations in bioink formulations, and improved printing speed and precision are key growth factor for instruments and reagents.
While bioprinting holds enormous promise for in vitro applications, the technology holds even greater potential for clinical, in vivo regenerative medicine applications. Already much progress has been made toward using bioprinting tissue constructs in a range of medical applications, including for artificial skin. Bioprinting meets this clinical need because it can not only make large patterns, but also simultaneously print living cells and scaffolds.
"The market for regenerative tissue products is large and growing rapidly," says BCC Research analyst John Bergin. “A key market segment will be products that create new tissue using stem cells and other primitive material components. 3-D printed human tissues can be used for organ-on-chip as well as for regenerative medicine applications."
Bioprinting: Technologies and Global Markets (BIO148A) analyzes the industry by workflow, including bioprinting reagents, instruments, software, clinical procedures, and tissue formats like tissue-on-chip. The report also examines the markets for the main bioprinting end-use applications, including research, drug discovery and development, cosmetics, and clinical. Global market drivers and trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
Bioprinting: Technologies and Global Markets( BIO148A )
Publish Date: Oct 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.